Sign In
Buy MRSN
$29.08
+0 (+0%)
At Close: Apr 02, 2026
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
01:58pm, Tuesday, 09'th Aug 2022 Benzinga
U.S. stocks traded mixed this morning, with the Nasdaq dropping around 90 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.06% to 32,853.24 while the NASDAQ fell 0.75% to 1
Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2022 Results - Earnings Call Transcript
10:36pm, Monday, 08'th Aug 2022
Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jason Fredette - Senior Vice President, Investor Relations and Corporate Commu
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates
09:15pm, Monday, 08'th Aug 2022 Zacks Investment Research
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Mersana Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results
08:04pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibod
Mersana Therapeutics Announces Option Agreement with GSK for the Co-Development and Commercialization of XMT-2056, an Immunosynthen ADC Targeting HER2
08:02pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
02:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 50% and 9.55%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the sto
Mersana Therapeutics to Host Second Quarter 2022 Conference Call on August 8, 2022 and Present at Upcoming Conferences
08:00am, Wednesday, 03'rd Aug 2022
CAMBRIDGE, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-d
Mersana Therapeutics Chief People Officer Carla Poulson Named One of Savoy Magazine’s 2022 Most Influential Black Executives in Corporate America
12:00pm, Friday, 22'nd Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody
How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%
01:55pm, Monday, 11'th Jul 2022 Zacks Investment Research
The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre
How Much Upside is Left in Mersana Therapeutics, Inc. (MRSN)? Wall Street Analysts Think 256%
11:36am, Monday, 11'th Jul 2022
The mean of analysts' price targets for Mersana Therapeutics, Inc. (MRSN) points to a 255.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 08'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
Beam Therapeutics Inc. (BEAM) Moves 11% Higher: Will This Strength Last?
12:51pm, Monday, 20'th Jun 2022 Zacks Investment Research
Beam Therapeutics Inc. (BEAM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Friday, 03'rd Jun 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-
